Royalty Pharma to Present at Goldman Sachs 47th Annual Global Healthcare Conference
核心洞察
Royalty Pharma (搜索) will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026, at 4:00 p.m. ET.
The company also announced it will report second quarter 2026 financial results on August 5, 2026, before U.S. markets open, with a conference call at 8:00 a.m. ET.
Royalty Pharma (搜索) holds royalties on more than 35 commercial products including Trikafta, Trelegy, Evrysdi, and Trodelvy, plus 19 development-stage product candidates.
Royalty Pharma (搜索) plc (Nasdaq: RPRX) has announced its participation in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026, at 4:00 p.m. ET. The webcast will be accessible from the company's "Events" page and will be archived for a minimum of thirty days following the presentation.
The conference appearance comes as Royalty Pharma (搜索) continues to solidify its position as the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry. Founded in 1996, the company collaborates with a broad spectrum of innovators, ranging from academic institutions and research hospitals to non-profits, small and mid-cap biotechnology companies, and leading global pharmaceutical firms.
Portfolio Breadth and Commercial Reach
Royalty Pharma (搜索)'s current portfolio includes royalties on more than 35 commercial products spanning multiple therapeutic areas. Notable assets include Vertex's Trikafta and Alyftrek, GSK's Trelegy, Roche's Evrysdi, Johnson & Johnson's Tremfya, Biogen's Tysabri and Spinraza, Servier's Voranigo, AbbVie and Johnson & Johnson's Imbruvica, Astellas and Pfizer's Xtandi, Pfizer's Nurtec ODT, and Gilead's Trodelvy. The portfolio also encompasses 19 development-stage product candidates, reflecting the company's ongoing commitment to funding innovation across the drug development lifecycle.
Dual Funding Model
Royalty Pharma (搜索) funds biopharmaceutical innovation through two complementary approaches. Direct funding occurs when the company partners with organizations to co-fund late-stage clinical trials and new product launches in exchange for future royalties. Indirect funding involves acquiring existing royalties from original innovators. This dual model allows Royalty Pharma to support innovation at multiple points along the development and commercialization continuum.
Upcoming Financial Disclosure
In a separate announcement, Royalty Pharma (搜索) confirmed it will report its second quarter 2026 financial results on Wednesday, August 5, 2026, before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day. A replay of the conference call and webcast will be archived on the company's website for at least 30 days.
Investors and stakeholders can access both the Goldman Sachs conference webcast and the second quarter earnings call through the "Investors" page of Royalty Pharma (搜索)'s website.